Institut National De La Sante Et De La Recherche Medicale

Assistance Publique-hopitaux De Paris

UniversitÉ Paris Descartes

UniversitÉ De Versailles—saint-Quentin-En-Yvelines

Universite Paris Diderot (paris Vii)

Inserm (institut National De La Sante Et De La Recherche Medicale)

Université Paris Diderot

Inserm

Hôpital Frédéric-henri Manhès

Chantal Boulanger

Alain Tedgui

Pierre-Louis Tharaux

Pierre-Emmanuel Rautou

Olivier Blanc-Brude

Sylvain Lejeune

Francois Lionnet

Dominique-Charles Valla

Gérard London

The present invention relates to methods for determining the risk of severe complications in hemolytic diseases. The present invention relates to a method for determining whether a patient suffering from sickle cell disease is at risk for a vaso-occlusive crisis comprising the steps consisting of i) determining the level of cell microparticles in a blood sample obtained from said patient and ii) determining the level of heme and/or hemoglobin contained in said cell microparticles. The present invention also relates to a method for a method the severe complication in hemolytic diseases comprising the steps consisting of i) determining the level of cell microparticles in a blood sample obtained from said patient and ii) determining the level of heme and/or hemoglobin contained in said cell microparticles. The present invention also relates to a method for preventing a vaso-occlusive crisis in a patient afflicted with by sickle cell disease comprising depleting the blood-borne microparticles laden in heme and hemoglobin from the blood of said patient.

Methods for treating vaso-occlusive crisis using non-modified annexin V

The present invention relates to a method for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension comprising the steps consisting of i) quantifying the levels of leuko-endothelial (CD31+/41&#x2212;), pan-leukocyte (CD11a+), lymphocyte (CD4+), erythrocyte (CD235a+) and hepatocyte-derived (cytokeratin-18+) microparticles in a blood sample obtained from the patient and ii) comparing said levels with predetermined reference values wherein a difference between the levels quantified at step i) and the predetermined reference values is indicative whether the patient is at risk of having clinically significant portal hypertension.

Methods and kits for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension

Growing community of inventors

Paris, France

Chantal Boulanger